Case Challenges in HIV Medicine Benefits, Barriers, & Best Practices in an Advancing Field

Richard A. Elion, MD; Eric S. Daar, MD; Seble G. Kassaye, MD, MS; Leandro A. Mena, MD, MPH


Jointly provided by the Postgraduate Institute for Medicine and Integritas Communications


This activity is supported by an independent educational grant from Gilead Sciences, Inc.


Richard A. Elion, MD (Course Chair)
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Program Description

Since the rapid initiation of antiretroviral therapy (ART) has become more widely available, identified barriers to more widespread adoption of this approach to HIV management—whether faced by patient, provider, or health care system—now need solutions. In this case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal implementation of rapid ART. Faculty will guide learners on the important role of patient navigators or linkage to care coordinators in assisting patients to successfully enroll at the clinic, navigate public or private health insurance or drug assistance programs to gain access to ART, and get referrals for needed support services, including counseling or housing assistance. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (eg, comorbidities, polypharmacy issues, and adverse events) associated with ART regimens in specific subpopulations, such as women or the aging population. The proliferation of treatment-switching strategies has made therapeutic selection increasingly complex; real-world cases can provide context for education on this challenging topic.

As HIV care progresses and new treatment options become available for initiating and switching ART regimens, clinicians must know the data, indications, contraindications, and potential for adverse events or drug-drug interactions when individualizing treatment plans. Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Target Audience

This activity is designed to educate human immunodeficiency virus (HIV) specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Implement the most recent guidelines on identifying, treating, and monitoring patients with HIV
  • Describe the benefits of rapid antiretroviral therapy (ART) and tactics to overcome clinician and system barriers to implementation
  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities


  • Recent Updates to the Department of Health and Human Services (DHHS) HIV Guidelines
  • Rapid Antiretroviral Therapy (ART) Protocols as a New Standard of Care
  • Optimizing Adherence and Retention in Care Across Patient Types
  • Staying Up to Date in an Advancing Field

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD: Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare. Honoraria: Gilead Sciences, Inc., ViiV Healthcare. Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD: Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc. Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS: Nothing to disclose

Leandro A. Mena, MD, MPH: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare. Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit:

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity.

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at

Media: Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

expiration 10/30/2021

type Webcast